Matthew Gumbleton, MD, PhD

Dr. Gumbleton's primary practice pearl for the management of patients with EGFR-mutated NSCLC in 2026: with very few exceptions, every treatment-naïve patient deserves frontline combination therapy.

Dr. Riess presents a 55-year-old male former light smoker with stage IV EGFR L858R adenocarcinoma, ECOG performance status 1, three small asymptomatic brain metastases (largest 8 mm) on baseline brain MRI, no TP53 or other high-risk co-mutation, employed as a remote software engineer with concern about preserving cognitive function and work capacity.

Dr. Riess presents a 52-year-old never-smoking woman with stage IV EGFR exon 19 deletion non-small cell lung cancer, performance status 0, full-time employment as a teacher, no significant comorbidities, and no baseline CNS metastases on brain MRI.

Dr. Riess addresses dose modification frequency in MARIPOSA: dose interruptions in 83% of patients, dose reductions in 59%, and any-agent discontinuation in 35%, with only 10% discontinuing all agents due to treatment-related adverse events.

Dr. Gumbleton discusses how proactive dermatologic management translates into day-to-day clinical practice for patients receiving amivantamab-lazertinib for EGFR-mutated NSCLC.

Dr. Riess presents the COCOON trial data, which evaluated a standardized prophylactic regimen for dermatologic adverse event management with amivantamab-lazertinib in patients with EGFR-mutated NSCLC.

Dr. Gumbleton explains the mechanism of action of amivantamab-lazertinib for clinicians treating patients with EGFR-mutated NSCLC.

Dr. Riess addresses the high rate of CNS metastasis development in EGFR-mutated NSCLC (25%-45%), noting that MARIPOSA's requirement for serial brain MRIs in all participants generated robust intracranial efficacy data.

Dr. Riess highlights TP53 co-mutation as one of the most compelling high-risk subgroups in EGFR-mutated NSCLC, asking Dr. Fidler how TP53 co-mutation status influences frontline treatment selection.

Dr. Jonathan Riess introduces the program on first-line treatment strategies in EGFR-mutated NSCLC, joined by Dr. Mary Jo Fidler and Dr. Matthew Gumbleton.

Learn practical systems for managing EGFR therapy side effects, triage tips, and what’s next for resistance in metastatic NSCLC.

Experts weigh EGFR L858R/TP53 stage IV NSCLC options, combo regimens and brain-met strategies to boost control, ease visits.

Experts weigh combo therapy for EGFR L858R/TP53 lung cancer with brain mets, balancing radiation and systemic options to cut visits.

Experts compare EGFR lung cancer first-line combos, weighing chemo vs amivantamab-lazurtnib toxicity, quality of life, and patient-centered choice.

Experts weigh NCCN category 1 value and show how serial brain MRIs shape EGFR lung cancer first-line treatment decisions.

This episode explores how overall survival data, toxicity profiles, and guideline categorizations inform frontline decision-making.

This segment frames the current first-line treatment landscape for EGFR-mutant metastatic non–small cell lung cancer and how it has evolved over two decades.